Study
| Phase 3, open label, randomized study (RELEVANCE) |
| Untreated grade 1-3a FL |
| R2 (n:513) or R-chemo (n:517), followed by rituximab maintenance |
Efficacy
| ORR: 61% and 65%, CR/CRu: 48% and 53% (p: 0.10) |
| PFS did not differ HR= 1.03 [95% CI, 0.84 to 1.27], P = .78) |
| 6 year PFS: 60% (95% CI, 55 to 64) and 59% (95% CI, 54 to 64) |
| 6 year OS: 89% in both groups |
Safety
| ≥ grade 5 TEAE: 9 patients and 6 patients |
| Second primary malignancies 57 (11%) patients and 67 (13%) patients |
J Clin Oncol. 2022 Aug 10;JCO2200843.
http://doi.org/10.1200/jco.22.00843
Reviewed by Hasan Cagri Yildirim, MD on Sep 20, 2022
